Veru Stock Price, News & Analysis

Veru (NASDAQ: VERU) announced positive topline results from its Phase 2b QUALITY clinical study evaluating enobosarm in combination with WEGOVY (semaglutide) for weight reduction. The study met its primary endpoint, demonstrating that enobosarm significantly preserved lean mass in patients receiving WEGOVY, with treated patients losing 71% less lean mass than those on WEGOVY alone.

Key findings include: patients on enobosarm lost 27% more fat mass than the control group, maintained similar total body weight loss, and showed reduced decline in physical function. The study involved 168 older patients (>60 years) over 16 weeks. In the placebo group, 32% of total weight loss was lean mass, while 42.6% experienced significant decline in stair climb power, compared to only 19.4% in the enobosarm group.

The company plans to proceed with Phase 3 trials following these positive results, with an anticipated sample size of 470 subjects over 52 weeks.

Veru Inc. (NASDAQ: VERU) has sold its FC2 Female Condom® business to clients managed by Riva Ridge Capital Management LP and co-investors for $18 million. The sale allows Veru to transform into a pure biopharmaceutical company, with estimated net proceeds of $12.5 million after deducting fees and premiums. The company will experience a significant workforce reduction of 90%, from 210 to 22 employees.

The company is currently focused on its Phase 2b QUALITY clinical trial evaluating enobosarm for muscle preservation and fat loss in patients using WEGOVY®, with topline results expected in January 2025. The transaction will also result in the termination of the Royalty Agreement with SWK Funding , eliminating $9.9 million in liabilities.

Veru Inc (NASDAQ: VERU) announced its upcoming presentation at the 17th International Conference of the Society on Sarcopenia, Cachexia, & Wasting Disorders in Washington, DC. The presentation, titled 'The use of muscle selective anabolics to make GLP-1 RA weight loss drugs more effective and precise,' is scheduled for December 6th, 2024, from 4:15 PM to 5:30 PM EST. The company, which focuses on developing medicines for muscle preservation, weight loss, oncology, and viral-induced acute respiratory distress syndrome, will showcase its research at this significant industry event.

Veru Inc. presented a meta-analysis of enobosarm's effects on body composition in older obese patients at ObesityWeek 2024. The analysis, based on four previous clinical trials, showed that enobosarm 3mg treatment led to better outcomes compared to placebo. By Day 147, enobosarm-treated subjects showed greater total weight loss (-2.93kg vs -2.11kg placebo), better lean mass preservation (-0.79kg vs -1.77kg placebo), and increased fat mass reduction (-2.05kg vs -0.05kg placebo). The drug was well-tolerated with no increase in gastrointestinal side effects.

Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company, has announced its participation in ObesityWeek, scheduled for November 3-6, 2024, in San Antonio, Texas. The company will present a meta-analysis of subjects from four randomized clinical trials supporting the potential of enobosarm to optimize weight loss. This presentation, titled "Meta-analysis of subjects from 4 randomized clinical trials supports the potential of enobosarm to optimize weight loss," is set for November 5, 2024, from 2:30 PM to 3:30 PM CDT at the Henry B. González Convention Center.

Veru focuses on developing innovative medicines for preserving muscle for high-quality weight loss, oncology, and viral-induced acute respiratory distress syndrome. The presentation at ObesityWeek aligns with the company's research efforts in weight management and muscle preservation.

Veru Inc. (NASDAQ: VERU) announced its participation in the World Obesity and Weight Management Congress, scheduled for October 24-26, 2024, in Baltimore, Maryland. The company will deliver a keynote presentation on October 25, 2024, from 9:40 AM to 10:20 AM EDT at the Best Western Plus Hotel & Conference Center.

The presentation, titled 'Advancing enobosarm, an oral novel Selective Androgen Receptor Modulator (SARM), to avoid muscle loss and augment fat loss when combined with a Glucagon-Like Peptide-1 Receptor Agonist (GLP-1 RA) drugs for potentially higher quality weight loss', will focus on the scientific support for combining enobosarm with GLP-1 receptor agonists to preserve muscle during weight loss.

Veru Inc. is a late clinical stage biopharmaceutical company developing innovative medicines for preserving muscle for high quality weight loss, oncology, and viral induced acute respiratory distress syndrome.

Veru Inc. (NASDAQ: VERU), a late-stage biopharmaceutical company, will present at the 2024 Cantor Global Healthcare Conference on September 18th at 1:55 PM Eastern Time. Dr. Mitchell Steiner, the company's Chairman, President, and CEO, will provide a corporate update focusing on Veru's Phase 2b clinical development program of enobosarm.

The presentation will highlight enobosarm's potential to enhance fat loss and prevent muscle loss when used in combination with GLP-1 drugs for weight loss. This aligns with Veru's mission to develop innovative medicines for preserving muscle in high-quality weight loss, oncology, and viral-induced acute respiratory distress syndrome.

Investors can access a live webcast of the presentation through Veru's website, with an archived version available afterward.

Veru Inc. (NASDAQ: VERU) has reached full enrollment of over 150 patients for its Phase 2b QUALITY clinical study of enobosarm in combination with semaglutide (Wegovy®) for obesity. The study aims to evaluate enobosarm's efficacy in preserving muscle mass and enhancing fat loss in patients using GLP-1 drugs for weight management. Topline data for the primary endpoint of lean body mass is expected in January 2025.

Financial highlights for Q3 FY2024 include:

• Net revenues increased to $4.0 million from $3.3 million
• Gross profit increased to $1.3 million from $1.2 million
• Research and development expenses decreased to $4.9 million from $8.8 million
• Net loss was $11.0 million, or $0.07 per share, compared to $12.5 million, or $0.14 per share

Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company, has announced it will host a conference call and audio webcast on August 8, 2024, at 8:00 a.m. ET to discuss its fiscal 2024 third quarter financial results and provide a business update. The company focuses on developing innovative medicines for preserving muscle for high quality weight loss, oncology, and viral induced acute respiratory distress syndrome.

Investors can access the audio webcast on Veru's website under the Investors page. To join the conference call, participants can dial 1-800-341-1602 (domestic) or 1-412-902-6706 (international). An archived version of the webcast will be available for replay on the company's website for approximately three months, and a telephonic replay will be accessible for one week.